Also Known as Advagraf ER (Tacrolimus)
Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
5mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Astagraf XL (tacrolimus extended-release capsules) is a prescription medication that is administered with other medications for preventing organ rejection in patients who have had a kidney transplant.
Astagraf XL comes in 0.5 mg, 1 mg, and 5 mg capsules for oral administration.
Fact Table | |
---|---|
Formula | C44H69NO12 |
License | FDA approved |
Bioavailability | Approximately 20-25% |
Legal status | Prescription only |
Chemical Name | (3S,4S,5R,8S,9E,12R,14R,15S,16R,18S,19S,26aR)-5,6,8,19-tetrahydroxy-4-methoxy-3-[(E)-2-[(1R,3R,4R)-4-methoxy-3-methylcyclohexyl]vinyl]-14,16-dimethoxy-13,18-dimethyl-3,4,5,6,8,12,15,16,17,18,19,20,21,22,23,24,25,26,26a-octadecahydro-3H-pyrido[2,1-c][1,4]oxaazacyclotetradecine-1,7,10,13,26-pentone |
Elimination half-life | Approximately 12 hours |
Dosage (Strength) | 0.5 mg, 1 mg, 5 mg extended-release capsules |
Pregnancy | Consult a healthcare provider |
Brands | Astagraf XL, Prograf |
Protein binding | 75-99% |
PubChem CID | 445643 |
MedlinePlus | a601117 |
ChEBI | 53198 |
ATC code | L04AD02 |
DrugBank | DB00864 |
KEGG | D01211 |
Routes of administration | Oral |
Astagraf XL should be taken as your doctor has instructed.
Your doctor will determine an appropriate dose for you based on other treatments you are receiving and how much you weigh.
The capsules should be taken whole and at the same time each morning; take on an empty stomach. Avoid consuming alcohol, grapefruit, or grapefruit juice.
Astagraf XL should be kept at 25°C (77°F).
Carefully read the medication guide that comes with your prescription for additional instructions for use.
Do not hesitate to reach out to your doctor or pharmacist with any questions or concerns regarding your prescription.
Tacrolimus is the active ingredient in Astagraf XL.
Ethylcellulose NF, hypromellose USP, magnesium stearate NF, lactose monohydrate NF, gelatin NF, titanium dioxide USP, ferric oxide NF, and sodium lauryl sulfate are the inactive ingredients.
Astagraf XL (tacrolimus) capsules should not be prescribed to patients with an allergy to tacrolimus.
Astagraf XL side effects include but are not limited to nausea, diarrhea, constipation, swelling, anemia, and tremor. Inform your doctor right away of any side effects that become bothersome or persistent.
Searching for a competitive Astagraf XL cost? Here, you can buy Astagraf XL.
Astagraf XL. Northbrook, IL: Astellas Pharma US, Inc.; 2023.